Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

Meyer, Jonathan M.; Davis, Vicki G.; Goff, Donald C.; McEvoy, Joseph P.; Nasrallah, Henry A.; Davis, Sonia M.; Rosenheck, Robert A.; Daumit, Gail L.; Hsiao, John K.; Swartz, Marvin S.; Stroup, T. Scott; Lieberman, Jeffrey A.

doi:10.1016/j.schres.2007.12.487

Cited by 246 publications

(167 citation statements)

References 49 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…Despite their widespread use, second-generation antipsychotics (SGAs), especially olanzapine and clozapine, have been associated with metabolic syndrome and the development of type 2 diabetes (Cohen and Correll, 2009;Meyer and Stahl, 2009;Yood et al, 2009). However, the risk of metabolic complications differs within the class of first-generation antipsychotics (FGAs) and SGAs, with high-potency FGAs and more recent SGAs, such as aripiprazole and ziprasidone, having smaller metabolic burden compared with the rest of the antipsychotic drugs (Meyer et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

Nielsen¹,

Skadhede²,

Correll³

2010

Neuropsychopharmacol

190

137

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

Nielsen¹,

Skadhede²,

Correll³

2010

Neuropsychopharmacol

190

137

View full text Add to dashboard Cite

“…The relationship between metabolic problems, such as obesity, diabetes and elevated lipids, and the expression of Apo has been frequently investigated in the general population (Padrao, Ferreira, Vitorino, & Amado, 2012;Ramachandran et al, 2012;Sadler et al, 2012). Due to antipsychotic medications in SZ and mood stabilisers in BD, those patients have an increased risk for metabolic disturbances and altered lipid metabolism (Gibbons, Thomas, Scarr, & Dean, 2010), ultimately contributing to an increased risk for cardiovascular disease (Meyer et al, 2008). Several authors observed an association between Apo concentrations in patients receiving psychiatric medication (e.g., phenothiazines, olanzapine, risperidone) (Dean et al, 2008;Sasaki et al, 1985;Smith, Segman, Golcer-Dubner, Pavlov, & Lerer, 2008;Song et al, 2014).…”

Section: Strength and Limitationsmentioning

confidence: 99%

Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder

Knöchel

Kniep

Cooper

et al. 2016

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Please note: Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders. AbstractProteomic analyses facilitate the interpretation of molecular biomarker probes which are very helpful in diagnosing schizophrenia. In the current study, we attempt to test whether potential differences in plasma protein expressions in schizophrenia (SZ) and bipolar disorder (BD) are associated with cognitive deficits and their underlying brain structures.42 plasma proteins of 29 SZ patients, 25 BD patients and 93 non-clinical controls were quantified and analysed using multiple reaction monitoring (MRM) based triple quadrupole mass spectrometry approach. We also computed group comparisons of protein expressions between patients and controls, and between SZ and BD patients, as well. Potential associations of protein levels with cognitive functioning (psychomotor speed, executive functioning, crystallized intelligence) as well as underlying brain volume in the hippocampus were explored, using bivariate correlation analyses.The main finding of this study was that apolipoprotein (ApoC) expression differed between patients and controls; and that these alterations in both disease groups were putatively related to cognitive impairments as well as to hippocampus volumes. However, none of the protein level differences were related to clinical symptom severity.In summary, altered apolipoprotein expression in BD and SZ was linked to cognitive decline and underlying morphological changes in both disorders. Our results suggest that the detection of molecular patterns in association with cognitive performance and its underlying brain morphology is of great importance for understanding of the pathological mechanisms of SZ and BD, as well as for supporting the diagnosis and treatment of both disorders.4

show abstract

“…Atypical antipsychotics are also associated with metabolic disorders, and vary in their propensity to cause these adverse effects [6]. In this regard, clozapine and olanzapine have the greatest liability, followed by quetiapine, risperidone, paliperidone, aripiprazole, and ziprasidone, according to the large automated database study [7] and the Clinical Antipsychotic Trials of Intervention Effectiveness study [8]. Recent studies have suggested weightindependent effects of certain atypical antipsychotics such as olanzapine or clozapine on insulin resistance that are above and beyond obesity [9,10].…”

Section: Troductiomentioning

confidence: 99%

Metabolic Effects of Sodium Valproate on Atypical Antipsychotics in Japanese Psychotic Patients

Nakamura¹,

Nagamine

2013

CNPT

View full text Add to dashboard Cite

Aim:To investigate the metabolic effects of atypical antipsychotics with or without sodium valproate (VPA) supplementation Methods: The anthropometrics and metabolic markers were reviewed in 132 Japanese psychotic patients treated with olanzapine, paliperidone, or aripiprazole. The outcome values and triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratios reflecting insulin resistance were compared at baseline and at 3 and 6 months in VPA-non-using (-VPA) patients and VPA-using (+VPA) patients for each atypical antipsychotic. Results: There were significant increases relative to baseline in body mass index (BMI) at 6 months in olanzapine/-VPA patients, and higher TG levels at 6 months in olanzapine/-VPA patients, olanzapine/+ VPA patients, and paliperidone/-VPA patients. The TG/HDL-C ratio at 6 months was significantly higher in olanzapine/+VPA patients and olanzapine/-VPA patients. Aripiprazole had no significant effects on these markers irrespective of whether or not VPA was used. Conclusion: Sodium valproate may produce different metabolic effects on body weight, lipid levels, and insulin resistance when combined with various atypical antipsychotics.

show abstract

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

Cited by 246 publications

References 49 publications

Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder

Metabolic Effects of Sodium Valproate on Atypical Antipsychotics in Japanese Psychotic Patients

Contact Info

Product

Resources

About